Intervacc (Q3 Review): Clinical progress, sales still slow - Redeye

Intervacc (Q3 Review): Clinical progress, sales still slow - Redeye

Q3 sales remained modest, while the reported loss was affected by an inventory write-down. Our focus remains on the potential 12-month label extension and progress towards the US market, where the efficacy study is due to start around year-end. We lower our base case to SEK1.6 (1.9), reflecting a higher WACC and updated financing assumptions.

Länk till analysen i sin helhet: https://www.redeye.se/research/1192924/intervacc-q3-review-clinical-progress-sales-still-slow?utm_source=finwire&utm_medium=RSS